.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its own top biopharma pick for 2025 and also rated one more 9 labels in the room as overweight. The assets bank mentioned in a note that it remains to think “diabesity is actually set to become.